Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $106M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| - | Atlas Vent... | atlasventu... |
| 13.05.2022 | Abingworth... | abingworth... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.11.2020 | Series B | $60M | - |
| 27.05.2020 | Series A | $46M | - |
Mentions in press and media 15
| Date | Title | Description |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 07.07.2021 | Q32 Bio Appoints Adam Cutler as Chief Financial Officer | |
| 04.11.2020 | Q32 Bio Raises $60M in Series B Financing | Q32 Bio, a Cambridge, Mass.-based biotechnology company developing biologic therapeutics to restore healthy immune regulation, closed a $60m Series B financing. The round was co-led by OrbiMed Advisors and Acorn Bioventures with participati... |
| 30.10.2020 | Q32 Bio secures US$ 60M in Series B funding | - |
| 29.10.2020 | Q32 Bio Closes $60 Million Series B Financing | Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures. The company also an... |
| 29.10.2020 | Q32 Bio grabs $60M to kick off human studies for next-gen complement drugs — with some Covid-19 tweaks along the way | For a company that launched in the early months of the pandemic, Q32 Bio had its fair share of run-ins with the new normals under Covid-19. Mike Broxson The original plan, for instance, was to conduct first-in-human studies of... |
| 29.10.2020 | Congratulations to Michael Broxson and team as Q32 Bio close a $60 Million Series B Financing, Advancing Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis | - |
| 29.10.2020 | Q32 Bio Scoops Up $60M Series B | CAMBRIDGE, MA, Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B round. >> Click here for more funding data on Q32 Bio ... |
| 29.10.2020 | Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis |
Show more